Food Allergy Immunotherapy Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Food Allergy Immunotherapy remains an active clinical development field. The landscape is diversifying across prevention, early treatment and high-risk populations, making variant coverage, resistance, seasonality and practical delivery central to differentiation. The PatSnap evidence set used here contains 289 matched trial records and 161 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07701954 | LCA-0061 | Phase 1; Recruiting | Lycia Therapeutics, Inc. | Canada | Occurrence of treatment-emergent adverse events (TEAEs) (Part A (SAD) Cohorts: Day 1 up to Day 36 - Part B (MAD) Cohorts: Day 1 up to…); Occurrence of TEAEs leading to discontinuation (Part A (SAD) Cohorts: Day 1 up to Day 36 - Part B (MAD) Cohorts: Day 1 up to…) | 2028-04-01 |
| NCT07687797 | Intervention not normalized | Not Applicable; Not yet recruiting | Ain Shams University | Egypt | determining the frequency of cow milk intolerance diagnosis among patients suspected for cow milk protein allergy (12 weeks) | 2027-08-01 |
| JPRN-jRCT1030260236 | Intervention not normalized | Phase 1; 募集前 | Sponsor not listed | Japan | Overall acceptability; 総合評価 | 2026-07-20 |
| ChiCTR2600126340 | Intervention not normalized | Not Applicable; Not yet recruiting | Zhongshan People's Hospital | China | Development of milk protein tolerance by the end of follow-up | 2028-04-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy (Phase 2): the indexed record reports Percentage of Participants Who Tolerated a Single Dose of >= 600 mg (1044 mg Cumulative Tolerated Dose) of Peanut Protein Without Dose-limiting Symptoms = 0.0 percentage of participants; Percentage of Participants Who Tolerated a Single Dose of >= 600 mg (1044 mg Cumulative Tolerated Dose) of Peanut Protein Without Dose-limiting Symptoms = 50.0 percentage of participants; Percentage of Participants Who Tolerated a Single Dose of >= 600 mg (1044 mg Cumulative Tolerated Dose) of Peanut Protein Without Dose-limiting Symptoms: Difference in Marginal Response Rate = 0.34(80% CI, 0.17 - 0.51); Posterior Probability = 0.989; Difference in Marginal Response Rate = 0.45(80% CI, 0.27 - 0.62); Posterior Probability = 0.997; Difference in Marginal Response Rate = 0.77(80% CI, 0.61 - 0.90); Posterior Probability = 1.000.
- Phase 2 Randomized Controlled Trial Using Biologics to Improve Multi OIT Outcomes (Phase 2): the indexed record reports The Success Rates of Passing a Peanut Double-Blind Placebo Controlled Food Challenge (DBPCFC) = 3 Participants; The Success Rates of Passing a Peanut Double-Blind Placebo Controlled Food Challenge (DBPCFC): Odds Ratio (OR) = 1.9(95% CI, 0.8 - 4.7), P-Value = 0.16; The Success Rates of Passing a Peanut Double-Blind Placebo Controlled Food Challenge (DBPCFC): Odds Ratio (OR) = 1.9(95% CI, 0.8 - 4.7), P-Value = 0.16.
- Immunonutritional effects elicited by a novel multicomponent food supplement in children with cow's milk allergy: results from a randomized, placebo-controlled trial (Phase 2): the indexed record reports Height(6-month) = 90.0 cm; -.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including LCA-0061 (Phase 1; IgE). Company & Deal Intelligence records identify sponsor context for Lycia Therapeutics, Inc., Ain Shams University, Zhongshan People's Hospital. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Clinically meaningful endpoints paired with virologic or microbiologic measures.
- Evidence in immunocompromised, pediatric, pregnant and older populations.
- Resistance surveillance and combination strategies for prolonged infection.
- Coadministration, real-world effectiveness and implementation studies.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Food Allergy Immunotherapy has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
